BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li JY, Chen YP, Li YQ, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer 2021;20:27. [PMID: 33541368 DOI: 10.1186/s12943-021-01317-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu S, Li Y, Zhu C, Wang W, Zhou Y, Natarajan N. Managing Cancer Drug Resistance from the Perspective of Inflammation. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/3426407] [Reference Citation Analysis]
2 Wang J, Jin J, Liang Y, Zhang Y, Wu N, Fan M, Zeng F, Deng F. miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma. Front Genet 2022;13:978840. [DOI: 10.3389/fgene.2022.978840] [Reference Citation Analysis]
3 Guo H, Ding P, Sun C, Yang P, Tian Y, Liu Y, Lowe S, Bentley R, Li Y, Zhang Z, Wang D, Li Y, Zhao Q. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial. Front Oncol 2022;12:927781. [DOI: 10.3389/fonc.2022.927781] [Reference Citation Analysis]
4 Zhang D, Lu W, Zhuo Z, Mei H, Wu X, Cui Y. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration. Discov Onc 2022;13. [DOI: 10.1007/s12672-022-00506-0] [Reference Citation Analysis]
5 Xu Z, Peng B, Kang F, Zhang W, Xiao M, Li J, Hong Q, Cai Y, Liu W, Yan Y, Peng J. The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian Cancer. Front Cell Dev Biol 2022;10:877254. [PMID: 35756990 DOI: 10.3389/fcell.2022.877254] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Li Z, Wu H, Zhu J, Sun L, Tong X, Huang D, Yang T. Novel Strategy for Optimized Nanocatalytic Tumor Therapy: From an Updated View. Small Science. [DOI: 10.1002/smsc.202200024] [Reference Citation Analysis]
7 Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A, Tabernero J. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol 2022. [PMID: 35535555 DOI: 10.2217/fon-2022-0093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Xiao K, Yang Z, Yan X, Liu Z, Yang M, Guo L, Cai L. Molecular Characteristics of m6A Regulators and Tumor Microenvironment Infiltration in Soft Tissue Sarcoma: A Gene-Based Study. Front Bioeng Biotechnol 2022;10:846812. [DOI: 10.3389/fbioe.2022.846812] [Reference Citation Analysis]
9 Jie X, Chen Y, Zhao Y, Yang X, Xu Y, Wang J, Meng R, Zhang S, Dong X, Zhang T, Yang K, Xu S, Wu G. Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer. J Immunother Cancer 2022;10:e003716. [PMID: 35121645 DOI: 10.1136/jitc-2021-003716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Huang Z, Chen H, Tan P, Huang M, Shi H, Sun B, Cheng Y, Li T, Mou Z, Li Q, Fu W. Sinapic acid inhibits pancreatic cancer proliferation, migration, and invasion via downregulation of the AKT/Gsk-3β signal pathway. Drug Dev Res 2021. [PMID: 34859906 DOI: 10.1002/ddr.21904] [Reference Citation Analysis]
11 Wang S, Zhou X, Zeng Z, Sui M, Chen L, Feng C, Huang C, Yang Q, Ji M, Hou P. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment. J Nanobiotechnology 2021;19:302. [PMID: 34600560 DOI: 10.1186/s12951-021-01034-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Tan P, Chen H, Huang Z, Huang M, Du Y, Li T, Chen Z, Liu Y, Fu W. MMP25-AS1/hsa-miR-10a-5p/SERPINE1 axis as a novel prognostic biomarker associated with immune cell infiltration in KIRC. Mol Ther Oncolytics 2021;22:307-25. [PMID: 34553021 DOI: 10.1016/j.omto.2021.07.008] [Reference Citation Analysis]
13 Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer 2021;161:26-33. [PMID: 34500218 DOI: 10.1016/j.lungcan.2021.08.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chen H, Shi T, Wang Y, Liu Z, Liu F, Zhang H, Wang X, Miao Z, Liu B, Wan M, Mao C, Wei J. Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy. J Am Chem Soc 2021;143:12025-37. [PMID: 34320319 DOI: 10.1021/jacs.1c03071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wharton KA Jr, Wood D, Manesse M, Maclean KH, Leiss F, Zuraw A. Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation. Front Mol Biosci 2021;8:672531. [PMID: 34386519 DOI: 10.3389/fmolb.2021.672531] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
16 Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. Oncoimmunology 2021;10:1950411. [PMID: 34290909 DOI: 10.1080/2162402X.2021.1950411] [Reference Citation Analysis]
17 Salewski I, Henne J, Engster L, Schneider B, Lemcke H, Skorska A, Berlin P, Henze L, Junghanss C, Maletzki C. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. Int J Mol Sci 2021;22:5990. [PMID: 34206051 DOI: 10.3390/ijms22115990] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
18 Ciccolella M, Andreone S, Mancini J, Sestili P, Negri D, Pacca AM, D'Urso MT, Macchia D, Canese R, Pang K, SaiYing Ko T, Decadt Y, Schiavoni G, Mattei F, Belardelli F, Aricò E, Bracci L. Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models. Cells 2021;10:845. [PMID: 33917958 DOI: 10.3390/cells10040845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 2021;9:513. [PMID: 33850910 DOI: 10.21037/atm-21-434] [Reference Citation Analysis]